No Idea in regards to the above.. I would love to know as...

No Idea in regards to the above.. I would love to know as well... but just saw this from etrade from an analyst:

Net sales for Axiron, Acrux's lead product out-licensed to Eli Lilly, for the quarter ended June 30, 2015 totaled USD 32.4 million, down 17% sequentially from USD 39.1 million and down 31% year on year. This amounts to a total fiscal 2015 net sales amount of USD 155.4 million, slightly higher than our forecasts, and translates to earned royalties from Axiron of USD 19.2 million compared with USD 22.3 million in the previous year. Encouragingly and based on IMS data for the United States, market share for the quarter remained steady at around 14% despite the negative overhang stemming from the U.S. Food and Drug Administration's drug safety communication in 2014. Nonetheless, we are mindful of the launch of Auxilium's new testosterone gel, Testim, Endo's 2% topical testosterone gel Fortesta, and Perrigo's generic version of AbbVie's low-strength testosterone treatment AndroGel 1.0% in the second half of 2014 and the potential for price erosion over the medium term. Our fair value estimate for no-moat-rated Acrux remains unchanged at AUD 1.10 per share pending the release of fiscal 2015 financial results on Aug. 13. This implies that the shares are undervalued at current levels and reflects the market's more negative view on growth prospects given the increasingly crowded competitive landscape. Acrux's no-moat and very high fair value uncertainty ratings remain intact, given its reliance on Eli Lilly to invest in sales and marketing of lead product Axiron.